T. Rowe Price Associates
MLYS icon

T. Rowe Price Associates’s Mineralys Therapeutics MLYS Stock Holding History

T. Rowe Price Associates’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61M Buy
2,262,476
+919,163
+68% +$25.2M 0.01% 827
2026
Q1 		$36.4M Buy
1,343,313
+18,193
+1% +$534K ﹤0.01% 872
2025
Q4 		$48.1M Buy
1,325,120
+1,303,737
+6,097% +$52.3M 0.01% 827
2025
Q3 		$811K Buy
21,383
+1,815
+9% +$39.3K ﹤0.01% 2154
2025
Q2 		$265K Buy
19,568
+7,151
+58% +$104K ﹤0.01% 2582
2025
Q1 		$198K Buy
12,417
+702
+6% +$8.07K ﹤0.01% 2643
2024
Q4 		$145K Buy
+11,715
New +$153K ﹤0.01% 2775

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

T. Rowe Price Associates's MLYS Position: Q2 2026 in Review

T. Rowe Price Associates increased its Mineralys Therapeutics (MLYS) stake by 68% in Q2 2026, buying an estimated $25.2M and bringing the position to 2,262,476 shares worth $61M. The position accounts for 0.01% of the portfolio, ranked #827.

T. Rowe Price Associates first reported a position in MLYS in Q4 2024 and has held it in 7 quarters since. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • T. Rowe Price Associates held 2,262,476 shares of Mineralys Therapeutics worth $61M as of Q2 2026.
  • T. Rowe Price Associates bought 919,163 Mineralys Therapeutics shares in Q2 2026, an estimated $25.2M.
  • Mineralys Therapeutics made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #827 holding.
  • T. Rowe Price Associates first reported a position in Mineralys Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.